ACUTE MYELOID LEUKEMIA (AML)

This study tested whether adding a drug called pevonedistat to the usual two-drug therapy (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 164 participants received either the …

This study tested whether adding the drug venetoclax to a mild chemotherapy (low-dose cytarabine) helps adults with acute myeloid leukemia (AML) live longer. The trial included 211 people aged 75+ or 18-74 with health issues that made strong chemo too risky. Results showed that t…

This study tested whether adding the experimental drug venetoclax to standard azacitidine works better than azacitidine alone for adults with untreated acute myeloid leukemia (AML) who cannot handle strong chemotherapy. About 443 participants received either the combination or a …

This study followed 8 adults in Germany with newly diagnosed acute myeloid leukemia (AML) who have a specific IDH1 mutation and cannot receive standard chemotherapy. They were treated with a combination of ivosidenib and azacitidine. The main goal was to measure their quality of …

This study looked at how safe and effective the drug venetoclax is for people with acute myeloid leukemia (AML), a rare and aggressive blood cancer. About 150 adults in South Korea took venetoclax pills as part of their normal treatment. Researchers tracked side effects and how w…

This study tested whether a combination of two drugs, venetoclax and azacitidine, can help keep acute myeloid leukemia (AML) from returning after patients achieve remission with standard chemotherapy. It involved 112 adults with AML who were in their first remission. The goal was…

This early-stage study tested a new drug called PRT2527, alone or combined with other medicines (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to check safety, find the best dose, and see i…

This study tested a new drug combination for adults newly diagnosed with acute myeloid leukemia (AML) that has a specific gene change (FLT3 mutation). Participants were not healthy enough for standard strong chemotherapy. The study compared the current standard drug (azacitidine)…

This study looked at how well a stem cell transplant works for 98 adults with acute myeloid leukemia (AML) who were in their first remission. Patients received a standard chemotherapy regimen before getting stem cells from a matched sibling, matched unrelated donor, or a half-mat…

This study tested a combined bone marrow and kidney transplant from a partially matched family donor for 10 people with both a serious blood disorder and chronic kidney disease. The goal was to treat both conditions with one donor, potentially reducing the need for lifelong anti-…

This study looked at 113 adults in Italy with certain types of acute myeloid leukemia (AML) who were treated with Vyxeos liposomal as part of their normal care. Researchers tracked how many patients achieved complete remission without signs of leftover disease. The goal was to se…

This completed study gathered real-world information from 112 adults in France with acute myeloid leukemia (AML) who were in remission and taking oral azacitidine as maintenance therapy. Researchers tracked how long patients stayed relapse-free, overall survival, and treatment pa…